- Home
- VERU
VERU
Veru Inc.
as 08-22-2025 10:36am EST
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
| Founded: | 1971 | Country: | United States |
| Employees: | N/A | City: | MIAMI |
| Market Cap: | 85.5M | IPO Year: | 1990 |
| Target Price: | $33.33 | AVG Volume (30 days): | 227.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.64 - $14.20 | Next Earning Date: | 08-12-2025 |
| Revenue: | $16,886,419 | Revenue Growth: | 337.24% |
| Revenue Growth (this year): | -83.39% | Revenue Growth (next year): | N/A |
Latest Veru Inc. News
VERU Breaking Stock News: Dive into VERU Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 months ago
Veru And Two Other Penny Stocks To Consider
GlobeNewswire
2 months ago
Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation
Simply Wall St.
2 months ago
One Veru Insider Raised Stake By 150% In Previous Year
GlobeNewswire
2 months ago
Veru to Participate in the Virtual BTIG Obesity Health Forum
BioPharma Dive
3 months ago
Muscle-sparing obesity drug safe for Phase 3 trial, Veru says
GlobeNewswire
3 months ago
Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone
GuruFocus.com
3 months ago
Veru Inc (VERU) Q2 2025 Earnings Call Highlights: Promising Clinical Results Amid Financial ...
GlobeNewswire
3 months ago
Veru Participates in a Virtual Investor KOL Connect Segment
Compare VERU vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VERU Veru Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.